Raymond James & Associates Mannkind Corp Transaction History

Raymond James & Associates

  • $161 Billion
  • Q3 2024

A detailed history of Raymond James & Associates transactions in Mannkind Corp stock. As of the latest transaction made, Raymond James & Associates holds 343,904 shares of MNKD stock, worth $2.09 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
343,904
Previous 323,650 6.26%
Holding current value
$2.09 Million
Previous $1.69 Million 27.83%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 18, 2024
BUY
$5.01 - $6.7 $101,472 - $135,701
20,254 Added 6.26%
343,904 $2.16 Million
Q2 2024

Jul 19, 2024
SELL
$4.05 - $5.43 $170,415 - $228,483
-42,078 Reduced 11.51%
323,650 $1.69 Million
Q1 2024

Apr 22, 2024
SELL
$3.25 - $5.27 $14,573 - $23,630
-4,484 Reduced 1.21%
365,728 $1.66 Million
Q4 2023

Jan 16, 2024
BUY
$3.34 - $4.29 $114,849 - $147,515
34,386 Added 10.24%
370,212 $1.35 Million
Q3 2023

Oct 24, 2023
BUY
$3.91 - $5.45 $211,319 - $294,550
54,046 Added 19.18%
335,826 $1.39 Million
Q2 2023

Jul 25, 2023
SELL
$3.72 - $4.79 $1.39 Million - $1.79 Million
-373,181 Reduced 56.98%
281,780 $1.15 Million
Q1 2023

Apr 14, 2023
BUY
$3.95 - $5.63 $140,991 - $200,957
35,694 Added 5.76%
654,961 $2.69 Million
Q4 2022

Feb 08, 2023
BUY
$3.02 - $5.37 $835,295 - $1.49 Million
276,588 Added 80.71%
619,267 $3.26 Million
Q3 2022

Oct 25, 2022
SELL
$2.99 - $4.35 $7,280 - $10,592
-2,435 Reduced 0.71%
342,679 $1.06 Million
Q2 2022

Aug 12, 2022
SELL
$2.67 - $4.77 $7,919 - $14,147
-2,966 Reduced 0.85%
345,114 $1.32 Million
Q1 2022

May 11, 2022
BUY
$2.62 - $4.45 $25,136 - $42,693
9,594 Added 2.83%
348,080 $1.28 Million
Q4 2021

Feb 08, 2022
SELL
$4.05 - $5.37 $35,291 - $46,794
-8,714 Reduced 2.51%
338,486 $1.48 Million
Q3 2021

Nov 02, 2021
BUY
$3.89 - $5.48 $8,663 - $12,203
2,227 Added 0.65%
347,200 $1.51 Million
Q2 2021

Aug 11, 2021
BUY
$3.61 - $5.45 $14,313 - $21,609
3,965 Added 1.16%
344,973 $1.88 Million
Q1 2021

May 14, 2021
BUY
$3.14 - $6.14 $154,101 - $301,332
49,077 Added 16.81%
341,008 $1.34 Million
Q4 2020

Feb 12, 2021
SELL
$1.79 - $4.04 $6,461 - $14,584
-3,610 Reduced 1.22%
291,931 $914,000
Q3 2020

Nov 04, 2020
SELL
$1.56 - $2.08 $88,271 - $117,694
-56,584 Reduced 16.07%
295,541 $556,000
Q2 2020

Jul 28, 2020
BUY
$0.94 - $2.21 $6,916 - $16,261
7,358 Added 2.13%
352,125 $616,000
Q1 2020

Apr 21, 2020
SELL
$0.84 - $1.76 $48,089 - $100,758
-57,249 Reduced 14.24%
344,767 $355,000
Q4 2019

Feb 12, 2020
BUY
$1.14 - $1.49 $20,745 - $27,115
18,198 Added 4.74%
402,016 $519,000
Q3 2019

Nov 07, 2019
BUY
$1.04 - $1.44 $17,328 - $23,993
16,662 Added 4.54%
383,818 $480,000
Q2 2019

Aug 06, 2019
BUY
$1.09 - $1.88 $2,064 - $3,560
1,894 Added 0.52%
367,156 $422,000
Q1 2019

May 06, 2019
BUY
$1.14 - $2.25 $32,561 - $64,266
28,563 Added 8.48%
365,262 $720,000
Q4 2018

Feb 11, 2019
BUY
$1.02 - $2.05 $79,432 - $159,643
77,875 Added 30.09%
336,699 $357,000
Q3 2018

Nov 14, 2018
BUY
$1.01 - $2.19 $43,221 - $93,718
42,794 Added 19.81%
258,824 $474,000
Q2 2018

Aug 14, 2018
BUY
$1.59 - $2.38 $113,956 - $170,576
71,671 Added 49.65%
216,030 $410,000
Q1 2018

May 14, 2018
SELL
$2.28 - $3.8 $27,804 - $46,341
-12,195 Reduced 7.79%
144,359 $329,000
Q4 2017

Feb 14, 2018
BUY
$2.28 - $6.71 $126,006 - $370,834
55,266 Added 54.56%
156,554 $363,000
Q3 2017

Nov 13, 2017
BUY
$1.15 - $2.29 $16,221 - $32,302
14,106 Added 16.18%
101,288 $220,000
Q2 2017

Aug 14, 2017
BUY
N/A
87,182
87,182 $123,000

Others Institutions Holding MNKD

# of Institutions
244
Shares Held
148M
Call Options Held
1.62M
Put Options Held
802K
View Full List

About MANNKIND CORP

MNKD Quotes by TradingView
  • Ticker MNKD
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 257,338,000
  • Market Cap $1.57B
  • Description
  • MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for endocrine and orphan lung diseases in the United States. It offers Afrezza, an inhaled insulin used to improve glycemic control in adults with diabetes. It also promotes Thyquidity to adult and pediatric endocri...
More about MNKD
Track This Portfolio

Track Raymond James & Associates Portfolio

Follow Raymond James & Associates and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

News

Stay updated on Raymond James & Associates with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email